Canadian Hypertension Education Program. Brief overview of 2004 recommendations.
Campbell
Norm
N
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002170:Canada; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D006266:Health Education / Q000458:organization & administration*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000175:diagnosis / Q000628:therapy*; D008019:Life Style; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012955:Societies, Medical
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin